SensPD Enters its First Round of Funding to Launch its Breakthrough Software Technology for the Early Detection of Autism in Newborns

TEL AVIV, Israel, January 11, 2018 /PRNewswire/ --

SensPD, an exciting up and coming start up from Israel, is on the path to revolutionize the digital health market with its proprietary method for the early objective detection of autism in newborns only a few hours after birth by interfacing with existing ear monitoring devices thus enabling diagnosis of autism in real-time. It has been clinically proven that early detection of autism allows for immediate intervention leading to over 90% success in ingraining social skills. Currently, there is no clinically proven solution for the early diagnosis of autism on the market.

Oto Acoustic Emission (OAE) is the sound emitted from the inner ear. OAE responses to standard vocal stimuli enable diagnosis of the inner ear's operation. OAE devices are used in every healthcare facility including those associated with child development. SensPD uses complex vocal stimuli to diagnose the brainstem's response through its control of OAE production.

"As the father of an autistic boy, SensPD is not only a company with great potential but a life-long dream come true," said Raffi Rembrand, Founder of SensPD. "Our goal is to help physicians and parents detect autism at the earliest stage possible and in real-time so that the appropriate measures can be taken to ensure the highest and most effective level of care for the child. We are in a unique position in the medical device market and find the right investors is critical for our continued success."

Backed by a solid advisory board and reputable management team, SensPD is primed for launch in a market estimated at over $1Billion. The company is currently in clinical trials and is looking to raise funds for their go-to-market launch set for late 2018.

About SensPD 

SensPD Ltd. was founded in January 2017 by Raffi Rembrand, father of a child diagnosed with autism. To date, the company has achieved several milestones, including intellectual property (IP) Portfolio - SensPD's IP includes a pending national phase (USA, Europe) and a provisional patent dealing with noisy OAE measurements. Collaboration with the major hospitals in Israel and the USA is currently underway through feasibility studies and clinical trials. The company plans to launch is product on a market-wide scale by the end of 2019.

Press Contact
Ms. Maayan Shahar
Business Development
[email protected]

SOURCE SensPD